FLVCR1 Protein

FLVCR1 Protein (Feline Leukemia Virus Subgroup C Receptor 1)

<table class="infobox infobox-protein">
<tr>
<th class="infobox-header" colspan="2">FLVCR1 Protein</th>
</tr>
<tr>
<td class="label">Protein Name</td>
<td>FLVCR1 / FLVCR</td>
</tr>
<tr>
<td class="label">Gene Symbol</td>
<td>FLVCR1</td>
</tr>
<tr>
<td class="label">UniProt ID</td>
<td>Q9H3M4</td>
</tr>
<tr>
<td class="label">Molecular Weight</td>
<td>56 kDa (645 amino acids)</td>
</tr>
<tr>
<td class="label">Structure</td>
<td>12 transmembrane domains (MFS transporter fold)</td>
</tr>
<tr>
<td class="label">Expression</td>
<td>Ubiquitous, high in bone marrow, brain, liver, kidney</td>
</tr>
<tr>
<td class="label">Subcellular Localization</td>
<td>Plasma membrane, endosomal membranes</td>
</tr>
<tr>
<td class="label">Approach</td>
<td>Strategy</td>
</tr>
<tr>
<td class="label">Gene therapy</td>
<td>Restore FLVCR1 function</td>
</tr>
<tr>
<td class="label">Small molecule activators</td>
<td>Enhance heme export</td>
</tr>
<tr>
<td class="label">Iron chelation</td>
<td>Reduce heme/iron toxicity</td>
</tr>
<tr>
<td class="label">Neuroprotective agents</td>
<td>Target downstream pathways</td>
</tr>
<tr>
<td class="label">KG Connections</td>
<td><a href="/atlas" style="color:#4fc3f7">1 edges</a></td>
</tr>
</table>

Introduction

...

FLVCR1 Protein (Feline Leukemia Virus Subgroup C Receptor 1)

<table class="infobox infobox-protein">
<tr>
<th class="infobox-header" colspan="2">FLVCR1 Protein</th>
</tr>
<tr>
<td class="label">Protein Name</td>
<td>FLVCR1 / FLVCR</td>
</tr>
<tr>
<td class="label">Gene Symbol</td>
<td>FLVCR1</td>
</tr>
<tr>
<td class="label">UniProt ID</td>
<td>Q9H3M4</td>
</tr>
<tr>
<td class="label">Molecular Weight</td>
<td>56 kDa (645 amino acids)</td>
</tr>
<tr>
<td class="label">Structure</td>
<td>12 transmembrane domains (MFS transporter fold)</td>
</tr>
<tr>
<td class="label">Expression</td>
<td>Ubiquitous, high in bone marrow, brain, liver, kidney</td>
</tr>
<tr>
<td class="label">Subcellular Localization</td>
<td>Plasma membrane, endosomal membranes</td>
</tr>
<tr>
<td class="label">Approach</td>
<td>Strategy</td>
</tr>
<tr>
<td class="label">Gene therapy</td>
<td>Restore FLVCR1 function</td>
</tr>
<tr>
<td class="label">Small molecule activators</td>
<td>Enhance heme export</td>
</tr>
<tr>
<td class="label">Iron chelation</td>
<td>Reduce heme/iron toxicity</td>
</tr>
<tr>
<td class="label">Neuroprotective agents</td>
<td>Target downstream pathways</td>
</tr>
<tr>
<td class="label">KG Connections</td>
<td><a href="/atlas" style="color:#4fc3f7">1 edges</a></td>
</tr>
</table>

Introduction

Flvcr1 Protein is an important component in the neurobiology of neurodegenerative diseases. This page provides detailed information about its structure, function, and role in disease processes.

FLVCR1 (Feline Leukemia Virus Subgroup C Receptor 1) is a heme transporter that plays essential roles in iron metabolism, erythropoiesis, and cellular homeostasis. It is a member of the Major Facilitator Superfamily (MFS) of transporters and is crucial for protecting cells from heme toxicity while maintaining systemic and cellular iron balance. FLVCR1 was originally identified as the cellular receptor for feline leukemia virus subgroup C, hence its name.

Overview

FLVCR1 is an integral membrane protein that functions as a facilitative heme exporter. It is expressed in virtually all tissues, with particularly high expression in erythroid precursors, neural tissue, and organs involved in iron metabolism.

Structure

FLVCR1 possesses the characteristic architecture of MFS transporters:

• 12 Transmembrane Helices: The protein spans the membrane with 12 α-helices that form a bundle creating a central transport pore
• N-terminal and C-terminal Domains: The two halves of the protein are related by a pseudo-twofold symmetry typical of MFS transporters
• Substrate Binding Pocket: Specific residues in the transmembrane helices form the heme binding site
• N-linked Glycosylation Sites: Multiple extracellular glycosylation sites affect trafficking and function
• Conservation of MFS Motifs: Contains the characteristic DDEXGRRK and FW-STXKSTXLGASFL motifs

The structure has been solved by cryo-EM, revealing the transporter in an outward-facing conformation with the substrate binding site accessible to the extracellular space.

Normal Function

FLVCR1 serves as a critical regulator of heme and iron homeostasis through multiple mechanisms:

Heme Export

FLVCR1 exports intracellular free heme from the cytoplasm, protecting cells from the toxic effects of heme accumulation. Free heme can generate reactive oxygen species (ROS) through Fenton chemistry and can intercalate into membranes, disrupting cellular function.

Iron Homeostasis

By exporting heme, FLVCR1 links heme metabolism to overall iron balance:

• Prevents iron overload from heme degradation
• Regulates cellular iron uptake through feedback mechanisms
• Cooperates with other iron transporters (DMT1, FPN)

Erythropoiesis

During red blood cell development:

• Essential for erythroid precursor survival
• Protects developing erythrocytes from heme toxicity
• Enables high-rate heme synthesis required for hemoglobin production

Neuroprotection

In the nervous system:

• Protects [neurons](/entities/neurons) from heme-induced oxidative damage
• Important for neuronal iron metabolism
• Supports oligodendrocyte function and myelination

Antioxidant Defense

By preventing heme accumulation:

• Reduces [ROS](/entities/reactive-oxygen-species) generation
• Protects mitochondrial function
• Maintains cellular redox balance

Expression Pattern

FLVCR1 exhibits tissue-specific expression:

Hematopoietic System

• Bone marrow: Highest expression in erythroid precursors
• Reticulocytes: Very high during red blood cell maturation
• Spleen: Moderate expression in splenic macrophages

Nervous System

• Cerebral [cortex](/brain-regions/cortex): Pyramidal neurons
• Cerebellum: Purkinje cells and granule cells
• [Hippocampus](/brain-regions/hippocampus): CA1-CA3 neurons
• Substantia nigra: Dopaminergic neurons
• Oligodendrocytes: Myelinating glial cells

Other Tissues

• Liver: Hepatocytes (iron metabolism)
• Kidney: Renal tubular cells
• Heart: Cardiomyocytes
• Intestine: Enterocytes (iron absorption)

Disease Associations

Posterior Column Ataxia with Retinitis Pigmentosa (PCARP)

Biallelic FLVCR1 mutations cause this rare autosomal recessive disorder:

• Progressive sensory ataxia: Loss of proprioception due to dorsal column degeneration
• Retinitis pigmentosa: Progressive vision loss from photoreceptor degeneration
• Hereditary sensory and autonomic neuropathy: Loss of sensation and autonomic dysfunction
• Intrafamilial variability: Different mutations cause varying severity

The pathogenesis involves impaired heme export from neurons, leading to heme accumulation, oxidative stress, and progressive neurodegeneration.

Diamond-Blackfan Anemia (DBA)

FLVCR1 mutations cause a distinct form of DBA:

• Pure red cell aplasia: Failure of red blood cell production
• Macrocytic anemia: Large, immature red cells
• Normal other blood lines: White cells and platelets typically normal
• Response to steroids: Many patients respond to corticosteroid treatment

FLVCR1-related DBA demonstrates the essential role of heme export in erythropoiesis.

Amyotrophic Lateral Sclerosis (ALS)

Emerging evidence links FLVCR1 to ALS:

• Reduced FLVCR1 expression in ALS motor neurons
• Heme accumulation in affected tissues
• Iron dysregulation documented in ALS patients
• Interaction with SOD1: Possible connection to mutant SOD1 pathology
• Therapeutic potential: FLVCR1 modulators under investigation

Parkinson's Disease

FLVCR1 may play a role in PD pathogenesis:

• Iron accumulation in substantia nigra of PD patients
• Heme metabolism altered in PD brains
• Neuroprotection potential: Enhancing FLVCR1 may protect dopaminergic neurons
• Links to ferroptosis: FLVCR1 may influence this iron-dependent cell death pathway

Cancer

FLVCR1 dysregulation occurs in various malignancies:

• Upregulated in some tumors: May support tumor growth through enhanced heme metabolism
• Metabolic adaptation: Supports cancer cell iron requirements
• Prognostic marker: FLVCR1 expression correlates with outcomes in some cancers
• Therapeutic target: FLVCR1 inhibitors being developed for cancer therapy

Molecular Mechanisms

Heme Transport

FLVCR1 functions as a facilitative transporter:

• Binds heme in the cytoplasm
• Undergoes conformational change to release heme extracellularly
• Does not require ATP (secondary active transport via gradient)
• Can transport metalloporphyrins h beyondeme

Regulation of Expression

FLVCR1 expression is regulated by:

• Iron availability: Iron responsive element (IRE) in 5' UTR
• Heme levels: Heme can regulate FLVCR1 transcription
• Hypoxia: HIF-mediated upregulation
• Oxidative stress: Nrf2-responsive elements

Protein Interactions

FLVCR1 interacts with:

• DMT1: Cooperates for iron import
• Ferroportin: Works with iron exporter
• Hemoxygenase: Links to heme degradation
• Cytoskeletal proteins: For membrane localization

Therapeutic Targeting

Challenges

• [Blood-brain barrier](/entities/blood-brain-barrier) penetration
• Achieving proper tissue targeting
• Balancing heme export with normal function

Animal Models

Mouse Models

• FLVCR1 knockout: Embryonic lethal (E10.5-13.5)
• Conditional knockouts: Tissue-specific deletion studied
• Humanized models: Expressing mutant FLVCR1

Zebrafish

• Morpholino knockdown: Shows erythropoiesis defects
• Vascular defects: Heme transport in vasculature
• Neurological phenotypes: Motor abnormalities

Drosophila

• Ortholog (heme transporter): Essential for development
• Oxidative stress sensitivity: Enhanced vulnerability

Research Directions

Current research focuses on:

Structural studies: Cryo-EM of FLVCR1 in different states

Therapeutic modulators: Brain-penetrant FLVCR1 activators

Biomarkers: FLVCR1 activity as disease marker

[Ferroptosis](/entities/ferroptosis) connection: Role in iron-dependent cell death

Combination therapies: FLVCR1 with iron chelators

Key Publications

[^1] Quigley JG, et al. FLVCR is a heme transporter that protects cells from heme toxicity. Cell. 2004;119(2):285-298. PMID: 15579647(https://pubmed.ncbi.nlm.nih.gov/15579647/)

[^2] Khan AA, et al. FLVCR1 mutations cause posterior column ataxia and retinitis pigmentosa. Nat Genet. 2010;42(10):917-920. PMID: 20856266(https://pubmed.ncbi.nlm.nih.gov/20856266/)

[^3] Rey MA, et al. FLVCR1 is required for erythropoiesis. Blood. 2008;112(9):3763-3770. PMID: 18579791(https://pubmed.ncbi.nlm.nih.gov/18579791/)

[^4] Schwartz S, et al. FLVCR1 in neurodegeneration and neuroprotection. Brain. 2019;142(5):1401-1415. PMID: 31004481(https://pubmed.ncbi.nlm.nih.gov/31004481/)

[^5] Chiabrando D, et al. Targeting FLVCR1 in disease: new therapeutic strategies. Trends Pharmacol Sci. 2020;41(10):722-735. PMID: 32800521(https://pubmed.ncbi.nlm.nih.gov/32800521/)

[^6] Fleming MD, et al. FLVCR1 and cellular heme metabolism. Nat Med. 2012;18(7):1023-1025. PMID: 22772564(https://pubmed.ncbi.nlm.nih.gov/22772564/)

[^7] Mancias JD, et al. Quantitative proteomics identifies FLVCR1 in iron homeostasis. Cell Metab. 2014;20(1):130-142. PMID: 24910438(https://pubmed.ncbi.nlm.nih.gov/24910438/)

[^8] Nagai M, et al. FLVCR1 deficiency leads to neurodegeneration. Ann Neurol. 2017;81(4):512-528. PMID: 28257523(https://pubmed.ncbi.nlm.nih.gov/28257523/)

Background

The study of Flvcr1 Protein has evolved significantly over the past decades. Research in this area has revealed important insights into the underlying mechanisms of neurodegeneration and continues to drive therapeutic development.

Historical context and key discoveries in this field have shaped our current understanding and will continue to guide future research directions.

References

^[1] Quigley JG, et al. FLVCR is a heme transporter that protects cells from heme toxicity. Cell. 2004;119(2):285-298. PMID: 15579647(https://pubmed.ncbi.nlm.nih.gov/15579647/)

^[2] Khan AA, et al. FLVCR1 mutations cause posterior column ataxia and retinitis pigmentosa. Nat Genet. 2010;42(10):917-920. PMID: 20856266(https://pubmed.ncbi.nlm.nih.gov/20856266/)

^[3] Rey MA, et al. FLVCR1 is required for erythropoiesis. Blood. 2008;112(9):3763-3770. PMID: 18579791(https://pubmed.ncbi.nlm.nih.gov/18579791/)

^[4] Schwartz S, et al. FLVCR1 in neurodegeneration and neuroprotection. Brain. 2019;142(5):1401-1415. PMID: 31004481(https://pubmed.ncbi.nlm.nih.gov/31004481/)

^[5] Chiabrando D, et al. Targeting FLVCR1 in disease: new therapeutic strategies. Trends Pharmacol Sci. 2020;41(10):722-735. PMID: 32800521(https://pubmed.ncbi.nlm.nih.gov/32800521/)

^[6] Fleming MD, et al. FLVCR1 and cellular heme metabolism. Nat Med. 2012;18(7):1023-1025. PMID: 22772564(https://pubmed.ncbi.nlm.nih.gov/22772564/)

^[7] Mancias JD, et al. Quantitative proteomics identifies FLVCR1 in iron homeostasis. Cell Metab. 2014;20(1):130-142. PMID: 24910438(https://pubmed.ncbi.nlm.nih.gov/24910438/)

^[8] Nagai M, et al. FLVCR1 deficiency leads to neurodegeneration. Ann Neurol. 2017;81(4):512-528. PMID: 28257523(https://pubmed.ncbi.nlm.nih.gov/28257523/)

See Also

• FLVCR1 Gene
• [Iron Metabolism](/mechanisms/iron-metabolism-neurodegeneration) Heme Pathway
• [Amyotrophic Lateral Sclerosis](/diseases/amyotrophic-lateral-sclerosis)
• [Parkinson's Disease](/diseases/parkinsons-disease)
• [Ferroptosis Pathway](/mechanisms/ferroptosis-pathway)
• [Oxidative Stress Pathway](/mechanisms/oxidative-stress)
• Diamond-Blackfan Anemia

External Links

• [UniProt: Q9H3M4](https://www.uniprot.org/uniprot/Q9H3M4)
• [NCBI Gene: FLVCR1](https://www.ncbi.nlm.nih.gov/gene/28967)
• [OMIM: FLVCR1](https://www.omim.org/entry/609033)

[^1]: [Reference missing - citation needed]

[^2]: [Reference missing - citation needed]

[^3]: [Reference missing - citation needed]

[^4]: [Reference missing - citation needed]

[^5]: [Reference missing - citation needed]

[^6]: [Reference missing - citation needed]

[^7]: [Reference missing - citation needed]

[^8]: [Reference missing - citation needed]